149 related articles for article (PubMed ID: 34796971)
1. Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis.
Gong H; Su Y; Zhao L; Ma L; Zhang L; Hou L; Li T; Niu S; Zhang H; Li C; Jin X; Ge L; Leng G; Liu Y
J Clin Pharm Ther; 2022 Apr; 47(4):493-506. PubMed ID: 34796971
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis.
Zhang C; Xiang Y; Wang J; Yan D
Front Oncol; 2023; 13():1118820. PubMed ID: 36937403
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
4. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T; Bai Y; Lin X; Li W; Wang J; Zhang X; Pan H; Bai C; Bai L; Cheng Y; Zhang J; Zhong H; Ba Y; Hu W; Xu R; Guo W; Qin S; Yang N; Lu J; Shitara K; Lei M; Li M; Bao N; Chen T; Shen L
Int J Cancer; 2023 Feb; 152(4):749-760. PubMed ID: 36121651
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
Wang J; Lin J; Wang R; Tong T; Zhao Y
BMC Cancer; 2024 May; 24(1):603. PubMed ID: 38760737
[TBL] [Abstract][Full Text] [Related]
6. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Mansoor W; Arkenau HT; Alsina M; Shitara K; Thuss-Patience P; Cuffe S; Dvorkin M; Park D; Ando T; Van Den Eynde M; Beretta GD; Zaniboni A; Doi T; Tabernero J; Ilson DH; Makris L; Benhadji KA; Van Cutsem E
Gastric Cancer; 2021 Jul; 24(4):970-977. PubMed ID: 33713215
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Jiang Y; Li Y; Wang LXW
Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
[TBL] [Abstract][Full Text] [Related]
8. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
Zheng Z; Guo Y; Zou CP
Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
Park S; Nam CM; Kim SG; Mun JE; Rha SY; Chung HC
Eur J Cancer; 2021 Feb; 144():49-60. PubMed ID: 33338727
[TBL] [Abstract][Full Text] [Related]
10. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials.
Zhao TT; Xu H; Xu HM; Wang ZN; Xu YY; Song YX; Yin SC; Liu XY; Miao ZF
Gastric Cancer; 2018 May; 21(3):361-371. PubMed ID: 29455269
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
Osawa M; Hasegawa M; Bello A; Roy A; Hruska MW
Cancer Chemother Pharmacol; 2019 Apr; 83(4):705-715. PubMed ID: 30666395
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis.
Cai T; Liang L; Zhao X; Lin C; Li D; Zheng J
Crit Rev Oncol Hematol; 2024 Jan; 193():104216. PubMed ID: 38029945
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
Chen LT; Oh DY; Ryu MH; Yeh KH; Yeo W; Carlesi R; Cheng R; Kim J; Orlando M; Kang YK
Cancer Res Treat; 2017 Oct; 49(4):851-868. PubMed ID: 28052652
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
16. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
[TBL] [Abstract][Full Text] [Related]
17. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M; Xiao H; Blum SI; Elimova E; Cella D; Shitara K; Ajani JA; Janjigian YY; Garrido M; Shen L; Yamaguchi K; Liu T; Schenker M; Kowalyszyn R; Bragagnoli AC; Bruges R; Montesarchio V; Pazo-Cid R; Hunter S; Davenport E; Wang J; Kondo K; Li M; Wyrwicz L
J Clin Oncol; 2023 Dec; 41(35):5388-5399. PubMed ID: 37713657
[TBL] [Abstract][Full Text] [Related]
18. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I; Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Sanchez T; Maglinte GA; Laurie M; Abraham P; Patel D; Shangguan T
Gastric Cancer; 2020 Jan; 23(1):133-141. PubMed ID: 31549264
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.
He YM; Yu C; Li WB; Li ZP; Xu N
J Cell Biochem; 2018 Jan; 119(1):1183-1192. PubMed ID: 28708307
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Shitara K; Doi T; Hosaka H; Thuss-Patience P; Santoro A; Longo F; Ozyilkan O; Cicin I; Park D; Zaanan A; Pericay C; Özgüroğlu M; Alsina M; Makris L; Benhadji KA; Ilson DH
Gastric Cancer; 2022 May; 25(3):586-597. PubMed ID: 34997449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
